Please assess the completion status of the following clinical trial:

Trial Title: Diabetic Retinopathy and Subclinical Signs of Disease Transition

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus type 1 or 2~* Age 18-90~Exclusion Criteria:~* Media opacities like cataract or vitreous hemorrhage~* Active intraocular inflammation (grade trace or above) in either eye like infectious conjunctivitis, keratitis, scleritis, endophthalmitis as well as idiopathic or autoimmune-associated uveitis in either eye~* Structural damage to the center of macula in the study eye~* Atrophy of retinal pigment epithelium, subretinal fibrosis, laser scar within foveal avascular zone (FAZ) or organized hard exudate plaques~* Ocular disorders in the study eye including retinal vascular occlusion, retinal detachment, macular hole, choroidal neovascularization, macula dystrophies~* Intraocular surgery (including cataract surgery, YAG laser capsulotomy) in the study eye within 3 months preceding Day 0, or history of corneal transplantation in the study eye~* Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication)or history of glaucoma filtration surgery~* Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed and graded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Intensified blood glucose control (Type: None): Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
- Nephropathy (Type: None): Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure

Based on this trial design, predict the completion outcome and termination type (if applicable).